Oncology Books
National Academies Press Breast Cancer and the Environment
a huge range and FREE tracked UK delivery on ALL orders.
£999.99
National Academies Press Reducing TobaccoRelated Cancer Incidence and Mortality
a huge range and FREE tracked UK delivery on ALL orders.
£999.99
National Academies Press The Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research Workshop Summary
a huge range and FREE tracked UK delivery on ALL orders.
£999.99
National Academies Press Examining Access to Nutrition Care in Outpatient Cancer Centers Proceedings of a Workshop
a huge range and FREE tracked UK delivery on ALL orders.
£999.99
National Academies Press Biological Effectors of Social Determinants of Health in Cancer
a huge range and FREE tracked UK delivery on ALL orders.
£999.99
Elsevier - Health Sciences Division Oncologic Imaging A Multidisciplinary Approach
Book SynopsisTable of Contents1 A Multidisciplinary Approach to Cancer: A Radiologist's View 2 A Multidisciplinary Approach to Cancer: A Surgeon's View 3 A Multidisciplinary Approach to Cancer: A Medical Oncologist's View 4 A Multidisciplinary Approach to Cancer: A Radiation Oncologist's View 5 Assessing Response to Therapy 6 Head and Neck Cancer 7 Lung Cancer 8 Primary Mediastinal Neoplasms 9 Pleural Tumors 10 Liver Cancer: Hepatocellular and Fibrolamellar Carcinoma 11 Cholangiocarcinoma 12 Pancreatic Ductal Adenocarcinoma 13 Cystic Pancreatic Lesions 14 Pancreatic Neuroendocrine Tumors 15 Esophageal Cancer 16 Gastric Carcinoma 17 Small Bowel Malignant Tumors 18 Colorectal Cancer 19 Renal Tumors 20 Urothelial Carcinoma (Bladder Cancer and Upper Tracts) 21 Testicular Germ Cell Tumors 22 Primary Adrenal Malignancy 23 Prostate Cancer 24 Primary Retroperitoneal Tumors 25 Tumors of the Uterine Corpus 26 Cervical Cancer 27 Ovarian Cancer 28 Breast Cancer 29 Myeloma and Leukemia 30 Hematologic Malignancy: The Lymphomas 31 Thoracic Metastatic Disease 32 Metastases Abdominal-Pelvic Organs 33 Peritoneal Cavity and Gastrointestinal Tract 34 Bone Metastases 35 Cancer of Unknown Primary 36 Imaging in Thyroid Cancer 37 Melanoma 38 Soft Tissue Sarcomas 39 Interventional Imaging in the Oncologic Patient 40 Complications in the Oncologic Patient: Chest 41 Complications in the Oncologic Patient: Abdomen and Pelvis 42 Pulmonary Embolic Disease and Cardiac Masses and Tumors 43 Protocols for Imaging Studies in the Oncologic Patient 44 Front Matter
£163.79
Elsevier - Health Sciences Division Clinical ImmunoOncology
Book SynopsisTable of ContentsTentative TOC: Introduction: Chapter 1.0 Development and Structure of the Lymphoid System embryologic development gross anatomy of the human immune system lymphatic endothelial cells, heterogeneity of, and lymph node microscopic structure lymph node function; afferent lymph cellular components role of the gut microbiome in immune system development specific functions related to the spread of cancer cancer-induced lymphangiogeneis; sentinel LNs Chapter 2.0 The Chemistry, Structure, and Function of Immunoglobulins immunoglobulin isotypes the structure of immunoglobulins the genetics of immunoglobulin diversity antibody-dependent cellular cytotoxicity heavy-chain C domain and role of glycosylation the development of humanized monoclonals Chapter 3.0 The Role of the Complement System in Cancer complement system activation pathways (classical, alternative and lectin) the role of complement activation in cancer progression complement regulatory proteins (CRPs) and cancer the role of compliment activation in the tumor microenvironment enhances tumor growth complement-dependent cytotoxicity in immune therapy of cancer formation of the membrane attack complex (MAC) potential application of anti-complement cancer therapies (C3aR/C5aR/IL-10 pathway) Chapter 4.0 Cancer as Non-Self 4.1 primary generator of tumor-specific transplantation type antigens 4.2 character of non-self, tumor associated antigens 4.3 immune surveillance - innate immunity 4.4 distinguishing between self and non-self 4.5 toll-like receptors (TLRs); soluble bioactive proteins such as cytokines and C' proteins 4.6 NK cells Chapter 5.0 The Adaptive Immune Response in Cancer the diversity of active tumor antigen receptors target specificity without limits in cancer-receptor variability tumor antigen presentation; dendritic cells immune response stimulation against the cancer Cytotoxic T-cells and T-regulatory cells B-cells and antibodies Chapter 6.0 The Science of Innate Immunity 6.1 critical regulator of human inflammatory disease 6.2 anatomic and physiologic barriers to pathogens - cancer causing viruses 6.3 centrally a limited number of critical receptors 6.4 the character of the inflammatory response 6.5 lack of ability to form memory 6.5 role in activating subsequent adaptive immune response Chapter 7.0 Immune Surveillance 7.1 history of concept (Ilya Mechnikov 1908 Nobel Prize) 7.2 evidence for immune surveillance today 7.3 cancer in the immunocompromised host Chapter 8.0 Cancer - Avoiding Immune Detection 8.1 cancer and the presence of immune resistance 8.2 concept for the development of tumor cell tolerance Chapter 9.0 Active Immunization Against Cancer and Cell-based Therapies 9.1 infusing in-vitro expanded Tumor Infiltrating Lymphocytes (TILs) 9.2 infusing dendritic cells pre-loaded with tumor specific oligopeptide antigens 9.3 B7 co-activating receptor 9.4 vaccines Chapter 10.0 The Three Major Clinical Components of Cancer Immunotherapy (modulating cell-mediated immune mechanisms) 10.1 the role of and application of check point blockade 10.2 the role and application of cell-based therapies including CAR-T cell therapies 10.3 antibodies (and vaccines); monoclonal antibodies and novel application of bi- or tri-specifics Chapter 11.0 The Clinical Application of Immunotherapeutics 11.1 in melanoma cancer 11.2 in breast cancer 11.3 in pancreatic cancer 11.4 in colon and rectum cancer 11.5 in prostate cancer 11.6 in leukemias and hematologic malignancies 11.7 in other malignancies Chapter 12.0 Cancer Immunotherapy in the Presence of COVID-19 12.1 immune response to coronavirus-2 infection 12.2 CD8+ T cell depression during chronic viral infection and cancer 12.3 checkpoint inhibitors in cancer patients with coronavirus infection 12.4 coronavirus depletion of CD4+ T cells
£102.59
Elsevier - Health Sciences Division Mosbys Oncology Nursing Advisor
Book SynopsisTable of ContentsSECTION ONE: INTRODUCTION Cancer Epidemiology: Implications for Prevention, Early Detection, and Treatment Cancer Pathophysiology Cancer Genetics / Genomics SECTION TWO: MAJOR CANCERS Breast Cancer Central Nervous System Cancers Gastrointestinal System Cancers Genitourinary Cancers Gynecologic Cancers Head and Neck Cancers Leukemias Lung Cancers Lymphomas Multiple Myeloma Myelofibrosis Neuroendocrine Cancers Sarcomas Skin Cancers SECTION THREE: PRINCIPLES OF CANCER MANAGEMENT Surgical Therapy Radiation Therapy Tumor Treating Fields Hematopoietic Stem Cell Transplantation Chemotherapy Targeted and Immunotherapy (Now a single chapter) Hormonal Therapy Oral Adherence Complementary and Alternative Therapies Clinical Trials SECTION FOUR: PRINCIPLES OF SYMPTOM MANAGEMENT Oncology Symptoms SECTION FIVE Oncologic Emergencies Structural Emergencies Urologic Emergencies Metabolic Emergencies Hematologic Emergencies SECTION SIX Palliative Care and End-of-Life Issues Survivorship Palliative Care Final Hours Loss, Grief, and Bereavement SECTION SEVEN Nursing Practice Considerations Communication Socio-Cultural Considerations Ethical Considerations Quality and Safety Evidence-Based Practice Nurse Navigation Patient Education Index
£60.79
Springer-Verlag New York Inc. Gastrointestinal Cancer MD Anderson Cancer Care Series
Book Synopsis- This clinical guidebook allows for quick, authoritative access to the latest and best multimodality therapies - Includes AJCC staging of gastrointestinal malignancies - Each chapter ends with an up-to-date list of suggested readings and ''key practice points'' making it a usefuly at-a-glance reference - Text includes 80 illustrations Trade ReviewFrom the reviews: "This is the third volume of the MD Anderson Cancer Care Series, detailing their standard approach to care of patients with gastrointestinal cancer. It emphasises the day-to-day aspects of medical care, minimising both extensive literature review and approaches not yet incorporated into routine practice. It is a pleasant soft-backed volume of 394 pages with 61 diagrams and scans; there are also liberal tables. … a useful addition to every departmental library." (Dr. C. L. Harmer, RAD Magazine, November, 2005)Table of ContentsStaging of Gastrointestinal Malignancies.- Recent Advances in Histopathology of Gastrointestinal Cancers: Prognostic and Therapeutic Assessment of Colorectal Cancers.- Current Status of Imaging Techniques in Gastrointestinal Cancers.- Endoscopy in the Management of Gastrointestinal Malignancies.- Role of Laparoscopy in Gastrointestinal Malignancies.- Risk Factors for Colorectal Cancer Susceptibility.- Colorectal Cancer: Screening and Primary Prevention.- Hereditary Nonpolyposis Colorectal Cancer and Genetic Counseling.- Colon Cancer.- Rectal Cancer.- Metastatic Cancer of the Liver.- Staging and Therapeutic Approaches for Patients with Localized, Potentially Curable Pancreatic Adenocarcinoma.- Treatment of Primary Liver Cancer.- Gastric Cancer.- Esophageal Carcinoma.- Anal Cancer.- Gastrointestinal Stromal Tumors.- Palliative Therapy.- Bowel Management in Patients with Cancer.- Barrett’s Esophagus.
£40.49
John Wiley & Sons Inc Tumor Microenvironment
a huge range and FREE tracked UK delivery on ALL orders.
£108.86
CRC Press Microcirculation in Cancer Metastasis
a huge range and FREE tracked UK delivery on ALL orders.
£118.75
Springer London Ltd Cancer Chemotherapy in Clinical Practice
Book SynopsisA simple introduction explaining the broad principles underlying chemotherapy, this book gives trainees a framework within which they can place the specific aspects of cancer chemotherapy they encounter in their everyday experience.Table of Contents1. The Theoretical Basis of Cancer Chemotherapy.- 2. Practical aspects of chemotherapy.- 3. Part III: Chemotherapy in the management of cancer.
£999.99
T.S.Aguilar Lifeline The Case for Effective Cancer
Book Synopsis
£18.75
Cambridge University Press Understanding Cancer
Book SynopsisOne in two of us will develop cancer at some point in our lives and yet many of us don''t understand how cancers arise. How many different kinds of cancer are there? What treatments are available? What does the future hold in terms of developing new therapies? This book demystifies cancer by explaining the underlying cell and molecular biology in a clear and accessible style. It answers the questions commonly asked about cancer such as what causes cancer and how cancer develops. It explains how DNA makes proteins and how mutations can corrupt those proteins. It also gives an overview of current therapies and how treatments may advance over the next decades, as well as explaining what actions we can take to help prevent cancer developing. Understanding Cancer is an accessible and engaging introduction to cancer biology for any interested reader.Trade Review'How often have we attended a lecture or opened a book to find that within minutes we are smothered by complicated facts that are way beyond our understanding? There has been no simple introduction. The speaker/author is so involved in the topic that they could no longer see out of the intellectual hole that they had dug for themselves. If ever a book was written to dispel this fault, then this is the one, as Robin Hesketh has managed to provide a remarkably clear and readable account of the science behind cellular behaviour and faults that lead to the development of cancer. The book reads like a novel, and I found that I could hardly put it down. The literary style is at times light-hearted with humorous analogies.' Robert Whitaker, anatomist, University of Cambridge'Understanding Cancer presents a carefully crafted, clear and concise book on aspects of cancer; a disease of importance to us all. Most readers will come to Robin Hesketh's book with questions about cancer. Understanding Cancer will not disappoint. The most usual questions and answers are presented in the first chapter and ways of reducing the risk of some cancers are suggested later. This book puts cancer into a historical and very interesting context; it then explores cancer, its biochemistry and functioning in an approachable way. Information is given about the latest treatments and the science behind them. This very readable book contains something for everyone. It is positioned, and very adequately fills, the gap between personal accounts by patients of their experiences, and more advanced medical and cell biology texts. Understanding Cancer is well researched and greatly recommended.' David Archer, schools liaison officer, British Society for Cell Biology'Understanding Cancer is a fascinating and engaging perspective on the evolution of cancer research and treatment. Dr Hesketh provides insight into the key clinicians and scientists, following their discoveries in clinical care and research. He overviews the likely mutagenic causes of cancer spurring on the oncogenic transitions leading to a cancer cell that can replicate uncontrollably, highlights new avenues in cancer research, and conveys that preventive measures and advances in early cancer detection could make an impact on cancer incidence and patient outcomes/survival. This book is certainly a triumph and a must-read for all current and future scientists, physicians at any stage of their professional careers and anyone interested in cancer research and the quest for effective anti-cancer treatments.' David Lyden, David Lyden, cancer researcher and paediatric oncologist, Weill Cornell Medicine, Cornell UniversityTable of Contents1. Painting a clear picture; 2. Ancient history; 3. Counting cancer; 4. From DNA to protein; 5. What is a cell?; 6. Mutations; 7. Causes of cancer that can be controlled; 8. Causes of cancer that are difficult to control, accidents … and other things; 9. Treating cancer by chemotherapy; 10. The road to utopia?
£11.99
CRC Press Surface Guided Radiation Therapy
Book SynopsisSurface Guided Radiation Therapy provides a comprehensive overview of optical surface image guidance systems for radiation therapy. It serves as an introductory teaching resource for students and trainees, and a valuable reference for medical physicists, physicians, radiation therapists, and administrators who wish to incorporate surface guided radiation therapy (SGRT) into their clinical practice. This is the first book dedicated to the principles and practice of SGRT, featuring: Chapters authored by an internationally represented list of physicists, radiation oncologists and therapists, edited by pioneers and experts in SGRT Covering the evolution of localization systems and their role in quality and safety, current SGRT systems, practical guides to commissioning and quality assurance, clinical applications by anatomic site, and emerging topics including skin mark-less setups. Several dedicated chapters on SGRT Trade Review“This book provides comprehensive, technically orientated information of surface guided radiation therapy, a rapidly emerging technology in radiotherapy. Authored by medical physicists, radiation therapists, and radiation vendors, this book covers all aspects of surface guided radiation therapy, with the intention of this new technology being implemented clinically in a safe and efficient manner. The book will likely be of greatest interest to residents of medical physics and radiation oncology as a textbook to gain general knowledge in the field, as well as to medical physicists as a reference book when implementing this new technology clinically. It may also be of interest to administration professionals who are considering expanding clinical practice and would like a general overview. This book is a timely addition to radiotherapy literature with a comprehensive collection of information and knowledge that has been gained in this emerging new field. While there are many research publications about surface guided radiotherapy already, this is the first book that encompasses technical information related to current SGRT systems on the market.” —Shuying Wan, PhD (Sidney Kimmel Cancer Center-Thomas Jefferson University) in Doody’s Core Titles Review 2022. Table of ContentsContents Preface, xi Acknowledgments, xiii Contributors, xv Chapter 1 ◾ A History of Surface Guidance Methods in Radiation Therapy 1 Jeremy D. P. Hoisak and Todd Pawlicki Chapter 2 ◾ Safety and Quality Improvements with SGRT 25 Hania A. Al-Hallaq and Bill J. Salter Chapter 3 ◾ Technical Overview and Features of the C-RAD Catalyst™ and Sentinel™ Systems 51 Karl Rasmussen, Victoria Bry, and Nikos Papanikolaou Chapter 4 ◾ Technical Overview and Features of the Varian IDENTIFY ™ System 73 Raymond Schulz, Chris Huyghe, Lisa Hampton, Delena Hanson, Michael stead, and Thomas Speck Chapter 5 ◾ Technical Overview and Features of the Vision RT AlignRT® System 95 Benjamin Waghorn Chapter 6 ◾ Commissioning and Routine Quality Assurance of the C-RAD Catalyst™ and Sentinel™ 4D-CT Systems 117 Alonso N. Gutierrez and Dennis N. Stanley Chapter 7 ◾ Commissioning and Routine Quality Assurance of the Varian IDENTIFY ™ System 137 Hui Zhao and Adam B. Paxton Chapter 8 ◾ Commissioning and Routine Quality Assurance of the Vision RT AlignRT® System 157 Guang Li Chapter 9 ◾ Surface Guidance for Whole Breast and Partial Breast: Technical Aspects 187 Laura Padilla Chapter 10 ◾ Surface Guidance for Breast: Deep Inspiration Breath Hold 209 Xiaoli Tang Chapter 11 ◾ Breast Cancer Outcomes and Toxicity Reduction with SGRT 227 Orit Kaidar-Person, Icro Meattini, Marianne C. Aznar, and Philip Poortmans Chapter 12 ◾ Surface Guidance for Stereotactic Radiosurgery and Radiotherapy: Technical Aspects 239 Laura Cerviño and Grace Gwe-Ya Kim Chapter 13 ◾ Clinical Outcomes of Intracranial Surface-Guided Stereotactic Radiosurgery 255 Douglas a. rahn iii Chapter 14 ◾ Risk Analysis for SGRT-Based SRS/SRT 269 Ryan Manger Chapter 15 ◾ SBRT and Respiratory Motion Management Strategies with Surface Guidance 279 Michael J. Tallhamer Chapter 16 ◾ The Use of SGRT for SBRT without Respiratory Gating 303 Ryan Foster and John Heinzerling Chapter 17 ◾ Head and Neck 319 Bo Zhao Chapter 18 ◾ Surface Image Guidance for Treatment of Extremities 339 David p. Gierga Chapter 19 ◾ Application of SGRT in Pediatric Patients: The CHLA Experience 351 Arthur J. Olch, Alisha Chlebik, and Kenneth Wong Chapter 20 ◾ Skin Mark-Less Patient Setup: A Physicist’s Perspective 367 Vanessa Panettieri, Sandra Paul, and Catherine Russell Chapter 21 ◾ Tattoo/Skin Mark-Less Setups Using SGRT: A Radiation Therapist’s Perspective 391 Jacqueline Dorney Chapter 22 ◾ Introducing SGRT into the Clinic: A Radiation Therapist’s Perspective 399 Ellen Herron and Daniel Bailey Chapter 23 ◾ SGRT for Proton Therapy 421 Adam B. Paxton Chapter 24 ◾ Integration of Surface Imaging with Tomographic and Bore-Type Gantry Treatment Systems 437 Lu
£45.99
CRC Press Cancer Targeting Therapies
Book SynopsisThis volume in the popular series, Drugs and the Pharmaceutical Sciences, begins with the history of cancer treatment, carcinogens, and molecular mechanisms involved in cancer pathogenesis. It incudes conventional and advanced cancer therapies ranging from oral and parenteral preparations to advanced fabricated systems such as nanoparticles, liposomes, antibodies, aptamers, poly(amidoamine) and photodynamic therapies. The preparation and mechanisms of molecular targeting of cancer are presented and the authors focus on a diverse audience including undergraduates and research students.Features Timely coverage of changes in process control technology for the phamaceutical industry, a dynamic area in terms of products and manufacturing processes Provides an update on the unique requirements of these industries and how they differ from others, for example the microelectronics or specialized chemicals industries Draws on the author's vast experience in the field of industrial hygiene and hazardous materials Presents a collection of unique situations in which industrial hygiene was implemented to resolve a variety of scenarios and did not interfere with quality issues Addresses current topics relating to industry evolution such as migration of therapies to higher potency, RiskMAP, new modalities in medicines and treatments, large molecule therapeutics and conjugates
£29.99
Taylor & Francis Ltd 50 Landmark Papers every Breast Surgeon Should
Book SynopsisThere has been an exponential increase in the volume and quality of published research relating to breast disease over the past decades. This book identifies the 50 key scientific articles in the field of breast disease and breast surgery and examines their importance and impact on current clinical care.Among thousands of articles, a small fraction are truly ''game changing''. Such studies form the foundations of breast surgery today, and the selection of papers within this book provide the 50 landmark papers every 21st-century breast surgeon needs to know. A commentary to each carefully selected paper explains why these papers are so important, thus providing every surgeon with the foundation stones of knowledge in this fast-moving area.A valuable reference not only to the established surgeon, but also to breast surgery residents and trainees, as well as to more experienced surgeons as they continue to learn new techniques and approaches and to improve their knowledge
£34.99
Springer-Verlag New York Inc. Urothelial Carcinoma
Book SynopsisThis fully updated volume explores recently improved avenues to study urothelial carcinomas.Table of ContentsPart I: Molecular Characterization 1. Scoring Systems for Immunohistochemistry in Urothelial Carcinoma Mark-Sebastian Bösherz, Iryna V. Samarska, and Nadine Therese Gaisa 2. A Panel-Based Method for the Reproduction of Distinct Molecular Subtype Classifications of Muscle-Invasive Urothelial Bladder Cancer Csilla Olah and Tibor Szarvas 3. Analysis of Mutational Signatures Using the mutSignatures R Library Damiano Fantini and Joshua J. Meeks 4. A Drug Repurposing Pipeline Based on Bladder Cancer Integrated Proteotranscriptomics Signatures Marika Mokou, Shaman Narayanasamy, Rafael Stroggilos, Irina-Afrodita Balaur, Antonia Vlahou, Harald Mischak, and Maria Frantzi 5. Characterization of Native COMPASS Complex in Urothelial Carcinoma Cells by Size Exclusion Chromatography Christoph Peter, Wolfgang A. Schulz, and Patcharawalai Whongsiri Part II: Urothelial Carcinogenesis 6. Reconstructing Phylogenetic Relationship in Bladder Cancer: A Methodological Overview Lancelot Seillier and Martin Peifer 7. Using Sister Chromatid Exchange Assay to Detect Homologous Recombination Deficiency in Epigenetically Deregulated Urothelial Carcinoma Cells Theodoros Rampias and Apostolos Klinakis 8. Identification of STAG2 Mutant Bladder Cancers by Immunohistochemistry Youngrok Park, Alana Lelo, Brent Harris, Deborah L. Berry, Krysta Chaldekas, Jung-Sik Kim, and Todd Waldman Part III: Cellular and Animal Models 9. Genome-Wide CRISPR Screening for the Identification of Therapy-Resistance-Associated Genes in Urothelial Carcinoma Klaus Mantwill and Roman Nawroth 10. Tissue Slice Culture and Analysis of Tumor-Associated Hyaluronan in Urothelial Carcinoma William Donelan, Paul L. Crispen, and Sergei Kusmartsev Part IV: Biomarkers 11. NGS-Based Tumor-Informed Analysis of Circulating Tumor DNA Iver Nordentoft, Karin Birkenkamp-Demtröder, and Lars Dyrskjøt 12. Considering the Effects of Modern Point-of-Care Urine Biomarker Assays in Follow-Up of Patients with High-Risk Non-Muscle Invasive Bladder Cancer Thorsten H. Ecke, Natalya Benderska-Söder, Ekkehardt Bismarck, Bas W.G. van Rhijn, Tilman Todenhöfer, and Bernd J. Schmitz-Dräger 13. Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations in Urine Samples for the Non-Invasive Diagnosis of Urothelial Cancer Maria Zvereva, Md Ismail Hosen, Nathalie Forey, Mahdi Sheikh, Caroline Kannengiesser, Ibrahima Ba, Arnaud Manel, Emmanuel Vian, and Florence Le Calvez-Kelm 14. Predictive Biomarkers of Response to Neoadjuvant Therapy in Muscle Invasive Bladder Cancer Jussi Nikkola and Peter Black 15. Assessment of PD-L1 Status in Urothelial Cancer Veronika Bahlinger, Arndt Hartmann, and Markus Eckstein Part V: Therapy Development 16. Epigenetic Priming and Development of New Combination Therapy Approaches Sarah Meneceur, Camilla M. Grunewald, Günter Niegisch, and Michèle. J. Hoffmann 17. Evaluation of FGFR Alteration Status in Urothelial Tumors Veronika Bahlinger, Markus Eckstein, Arndt Hartmann, and Robert Stöhr 18. Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma Günter Niegisch 19. Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder Cancer Paola Grandi, Andrea Darilek, Anay Moscu, Anu Pradhan, and Roger Li 20. Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and Oncolysis by Coxsackie Virus A21 Kate Relph, Mehreen Arif, Hardev Pandha, Nicola Annels, and Guy R. Simpson
£179.99
John Wiley and Sons Ltd The Role of the Clinical Nurse Specialist in
Book SynopsisThe Role of the Clinical Nurse Specialist in Cancer Care Gain a fresh and insightful perspective on the evolving role of the Clinical Nurse Specialist in the delivery of cancer services. The Role of the Clinical Nurse Specialist in Cancer Care explores the dynamic and essential world of the Clinical Nurse Specialist (CNS) in cancer care, covering both foundational and advanced topics and rooted in robust research and evidence-based practice. Trace the historical development of the CNS role while gaining invaluable patient and carer perspectives that provide essential guidance for professionals in this fieldExamine key aspects such as symptom management and non-medical prescribing, gaining a deeper understanding of the multifaceted responsibilities of Clinical Nurse SpecialistsFind vital subjects like leadership and multidisciplinary teamwork supplemented with practical tools to excel in your roleExplore comprehensive coverage of specialised areas within clinical nursing, including the unique challenges of caring for young adults with cancer, navigating the complexities of COVID-19, and utilising digital tools for enhanced patient care Whether you are a registered nurse aspiring to become a clinical nurse specialist or an established CNS seeking professional growth, The Role of the Clinical Nurse Specialist in Cancer Care provides invaluable insights and development opportunities. This engaging resource is also an excellent companion for advanced practitioners specialising in cancer care, ensuring they stay up-to-date with the latest advancements in this vital field.Table of ContentsList of Contributors xiv Foreword xvi Introduction xviii About the Companion Website xxi 1 Evolvement of Advanced Nursing Practice 1 Helen Kerr 1.1 Introduction 1 1.2 Evolvement of Nursing as a Profession 1 1.3 Advanced Nursing Practice 3 1.3.1 Criteria Associated with Advanced Nursing Practice 4 1.3.2 Advanced Practice Nurse Roles 6 1.3.3 Regulation 8 1.3.4 Components of Advanced Practice Nurse Roles 8 1.3.5 Education Requirements 8 1.3.6 Outcomes Associated with Advanced Practice Nurse Roles 9 1.3.7 Barriers to Advanced Practice Nursing Roles 9 1.3.8 Recommendations for Advanced Practice Nurse Roles 10 1.4 Conclusion 10 References 11 2 Emergence and Evolvement of the Clinical Nurse Specialist Role in Cancer Care 15 Helen Kerr 2.1 Introduction 15 2.2 Advanced Nursing Practice 15 2.3 Historical Context 16 2.4 Specialists vs. Generalists 17 2.5 Definition of a CNS 18 2.5.1 Role Blurring 18 2.6 Components of the Clinical Nurse Specialist Role 19 2.6.1 Direct Patient Care 20 2.6.2 Indirect Care 20 2.7 Professional Standards 21 2.8 Education Requirements 22 2.8.1 Impact of a Master’s Qualification 22 2.9 Outcomes of the Clinical Nurse Specialist Role 23 2.9.1 Outcomes Associated with the Clinical Nurse Specialist in Cancer Services 24 2.10 Specialist Practice in Cancer Care 25 2.11 Future Direction of the CNS 25 2.12 Conclusion 25 References 26 3 Patient Perspective 31 Johanna McMullan References 40 4 Carer’s Perspective 43 Trevor Wightman 5 Key Worker Role 49 Karen Armstrong and Helen Kerr 5.1 Introduction 49 5.2 The Key Worker 50 5.2.1 Provision of Information 52 5.2.2 Provision of Emotional and Supportive Care 52 5.2.3 Coordination of Services 53 5.3 Key Worker/Clinical Nurse Specialist Impact on Direct and Indirect Patient Care 54 5.4 Challenges in Practice 55 5.5 ‘First Impressions Count’ 57 5.6 Example of Change in Practice 58 5.7 Conclusion 59 References 59 6 Psychological Support 63 Caroline McCaughey, Edel Aughey, and Susan Smyth 6.1 Introduction 63 6.2 Part One: The Impact of a Cancer Diagnosis 64 6.2.1 Time Point One: Breaking Significant News 66 6.2.2 Time Point Two: Treatment Decision-Making 70 6.2.3 Time Point Three: Survivorship and Resilience 71 6.2.4 Fear of Recurrence 73 6.3 Part Two: Self-Care and the Clinical Nurse Specialist 74 6.4 Conclusion 77 References 78 7 Integrating Research and Evidence-Based Practice 84 Adrina O’Donnell, Ruth Boyd, and Clare McVeigh 7.1 Introduction 84 7.2 Evidence-Based Practice 85 7.3 Barriers to the Implementation of Evidence-Based Practice in the Clinical Setting 86 7.4 Role of Evidence-Based Practice in Caring for Patients with Cancer and Their Carers 87 7.5 Providing Evidence-Based Care as a Clinical Nurse Specialist 87 7.6 Clinical Application of Evidence-Based Practice by Clinical Nurse Specialists 88 7.7 Cancer Research and Clinical Trials 89 7.8 Cancer Clinical Trials, Research Nurses and the Role of the Clinical Nurse Specialist 91 7.9 The Role of the Clinical Nurse Specialist Along the Cancer Clinical Trial Patient Pathway 92 7.10 Conclusion 97 References 98 8 Symptom Management 104 Michelle Keenan and Helen Kerr 8.1 Introduction 104 8.2 Pain 105 8.2.1 Renal Impairment 107 8.2.2 Hepatic Impairment 108 8.2.3 Neuropathic Pain 109 8.3 Breathlessness 110 8.4 Nausea and Vomiting 112 8.5 Constipation 115 8.6 Conclusion 115 References 116 9 Multidisciplinary Teamworking 124 Hinal Patel and Oonagh McSorley 9.1 Introduction 124 9.2 The Multidisciplinary Team 125 9.2.1 Characteristics of an Effective Multidisciplinary Team 126 9.2.1.1 The Team 126 9.2.1.2 Multidisciplinary Meeting Organisational Logistics 128 9.2.1.3 Infrastructure for the Multidisciplinary Meeting 128 9.2.1.4 Person-Centred Clinical Decision-Making 128 9.2.1.5 Team Governance 129 9.3 The Role of the Clinical Nurse Specialist in Relation to the Multidisciplinary Team 129 9.3.1 Challenges of the Clinical Nurse Specialist Working in a Team 130 9.4 Conclusion 132 References 133 10 Leadership and the Clinical Nurse Specialist 136 Ruth Thompson and Monica Donovan 10.1 Introduction 136 10.2 Leadership 137 10.3 Self-Recognition of the Clinical Nurse Specialist as a Leader 137 10.4 Leadership in the Context of the Clinical Nurse Specialist 139 10.4.1 Clinical Leadership 140 10.4.1.1 Clinical Expertise and Coordination of Care 141 10.4.2 Professional Leadership 142 10.4.2.1 Enhancing Practice 143 10.4.2.2 Service Improvement and Innovation 143 10.4.2.3 Collaborative Working 144 10.5 Conclusion 144 References 144 11 Nurse-Led Clinics 149 Shelley Mooney and Helen Kerr 11.1 Introduction 149 11.2 Nurse-Led Care and the Launch of Nurse-Led Clinics in Healthcare 150 11.3 Components of a Nurse-Led Clinic 151 11.4 Introducing a Nurse-Led Clinic 152 11.5 Nursing Skills Required to Introduce and Establish a Nurse-Led Clinic 154 11.6 Approaches to Delivering a Nurse-Led Clinic 155 11.7 Patient Outcomes Related to Nurse-Led Clinics 156 11.8 Benefits of Nurse-Led Clinics for the Registered Nurse 157 11.9 Benefits of Nurse-Led Clinics for the Healthcare Organisation 157 11.10 Challenges to Implementing Nurse-Led Clinics 158 11.11 Nurse-Led Clinic Service Evaluation 159 11.12 Future of Nurse-Led Clinics 159 11.13 Reflection on the Role as a Uro-Oncology CNS Undertaking Nurse-Led Clinics 160 11.14 Conclusion 161 References 162 12 Non-Medical Prescribing 166 Laura Croan and Barry Quinn 12.1 Introduction 166 12.2 Background 167 12.3 Developments in Nursing Practice and the Role of Prescribing 168 12.3.1 Community Nurse Prescribing 168 12.3.2 Clinical Management Plans 169 12.3.3 Patient Group Directives 169 12.3.4 The Growth of Independent Prescribing 170 12.4 Preparing to Prescribe 172 12.5 Benefits and Challenges of Non-Medical Prescribing 172 12.6 Deciding to Become a Non-Medical Prescriber 173 12.7 Conclusion 177 References 178 13 Cancer in the Adolescent and Young Adult 181 Kerrie Sweeney and Helen Kerr 13.1 Introduction 181 13.2 Background to Adolescent and Young Adult Cancer Services 182 13.3 Person-Centred Adolescent and Young Adult Care 185 13.4 Support for Family and Significant Others 185 13.5 Holistic Care 186 13.6 Multidisciplinary Working 187 13.7 Healthcare Professional Knowledge 188 13.8 Adolescent and Young Adult Clinical Nurse Specialist Leadership Skills 189 13.9 Communication with Adolescents and Young Adults 189 13.10 Age-Appropriate Environments 191 13.11 Adolescent and Young Adult Peer Support 192 13.12 Adolescent and Young Adult Treatment Priorities 192 13.13 Transitional Adolescent and Young Adult Care 193 13.14 Living With and Beyond Cancer 194 13.15 Late Effects of Cancer Treatment 195 13.16 Palliative Adolescent and Young Adult Care 195 13.17 Co-production 196 13.18 Conclusion 196 References 197 14 COVID-19 and the Clinical Nurse Specialist 203 Stephanie Todd and Helen Kerr 14.1 Introduction 203 14.2 Impact on Healthcare Services and Frontline Healthcare Workers 204 14.3 Impact of COVID-19 on Cancer Services 205 14.4 The Role of the Clinical Nurse Specialist Prior to the COVID- 19 Pandemic 207 14.5 Devolvement of Staff over the COVID-19 Pandemic 208 14.6 Impact of COVID-19 on the Clinical Nurse Specialist Role and Patient Care 209 14.7 The Future of Healthcare Services Post–COVID-19 Pandemic 212 14.8 Conclusion 213 References 214 15 Digital Health 218 Amy Vercell and Sarah Hanbridge 15.1 Introduction 218 15.2 The Role of the Informatics Nurse/Chief Nursing Information Officer 220 15.3 Electronic Observations 220 15.4 Electronic Health Records 221 15.5 Digitalisation of Blood Glucose Monitoring 222 15.6 Electronic Nurse Prescribing 223 15.7 Nurse Digitally Requesting Bloods 224 15.8 Remote Consultations 224 15.9 Virtual Wards 225 15.10 Electronic Patient-Reported Outcome Measures 226 15.11 Mobile Cancer Applications 227 15.12 Home Blood Monitoring 228 15.13 Artificial Intelligence 229 15.14 Barriers to Digital Health 230 15.15 Conclusion 230 References 231 16 Future Direction of the Clinical Nurse Specialist in Cancer Care 236 Barry Quinn and Helen Kerr 16.1 Introduction 236 16.2 The Role of Caring and the Clinical Nurse Specialist 238 16.3 Developing Skills for Today and the Future 239 16.4 Leadership 240 16.5 Equality, Diversity and Inclusion in the Role of the Clinical Nurse Specialist 242 16.6 New Ways of Working 244 16.7 Self-Reflection 246 16.8 Conclusion 246 References 247 Index 250
£42.74
Springer-Verlag New York Inc. Oncofertility Medical Practice
Book SynopsisOncofertility is a specialty that bridges the disciplines of reproductive endocrinology and infertility and oncology, with the goal of expanding the reproductive options of cancer patients.Trade ReviewFrom the reviews:“The book has 15 chapters, divided into five parts. In addition there are seven appendices. There are 25 contributors, all from USA. … This is an excellent review of oncofertility, not only for gynecologists, but also for other specialties handling children and reproductive age men and women with cancer.” (Tom Tanbo, AOGS Acta Obstetricia et Gynecologica Scandinavica, Vol. 92 (1), January, 2013)“Oncofertility Medical Practice: Clinical Issues and Implementation has successfully contrived to bring together an understanding of the theoretical principles of gonadal effects of cancer therapy with all the clinical and practical aspects of fertility preservation for cancer survivors. The book should be read by both oncologist and fertility specialists, as it presents clearly the degree of overlap that is required by the different healthcare providers to achieve a meaningful outcome for the cancer patient. … This is a comprehensive and very well-written book … .” (Nivedita Reddy, The Obstetrician & Gynaecologist, Vol. 15 (2), 2013)Table of ContentsPart I Fertility Risks for Cancer Patients 1 Gonadotoxicity of Cancer Therapies in Pediatric and Reproductive-Age Females Jennifer Levine 2 Gonadotoxicity of Cancer Therapies in Pediatric and Reproductive-Age Males Jill P. Ginsberg Part II Options for Preserving Fertility 3 Fertility Preservation in Males Robert Brannigan 4 Embryo and Oocyte Banking Lynn M. Westphal and Jamie A.M. Massie 5 Ovarian Tissue Cryopreservation and Transplantation Laxmi Kondapalli, MD, MS 6 The Role of In Vitro Maturation in Fertility Preservation Peter S. Uzelac, Greg L. Christiansen, and Steven T. Nakajima 7 Mitigating the Risk: The Role of Ovarian Transposition and Medical Suppression Jaime M. Knopman and Nicole Noyes Part III: Care of the Oncofertility Patient 8 The Birds and the Bees and the Bank: Talking With Families About Future Fertility Amidst a Cancer Diagnosis Gwendolyn P. Quinn, Caprice A. Knapp, and Devin Murphy 9 Addressing the Three Most Frequently Asked Questions of a Bioethicist in an Oncofertility Setting Lisa Campo-Engelstein 10 Pregnancy in Cancer Patients and Survivors Eileen Wang 11 Communication Between Oncofertility Providers and Patients Jennifer Mersereau Part IV Oncofertility in Clinical Practice 12 Setting up an Oncofertility Program H. Irene Su, Lindsay Ray, and R. Jeffery Chang 13 Patient Navigation and Coordination of Care for the Oncofertility Patient: A Practical Guide Kristin Smith, Brenda Efymow, and Clarisa Gracia 14 Preparing an Interdisciplinary Workforce in Oncofertility – A suggested educational and research training program Christos Coutifaris Part V Clinical Cases in Oncofertility and Resources 15 Clinical Cases in Oncofertility 16 Appendices
£999.99
Springer-Verlag New York Inc. Hormonal Carcinogenesis II
Book SynopsisFor those of us who have labored in the field of hormonal carcinogenesis, it has been most gratifying to see its rapid growth and increasing relevance in recent years. Although many factors and forces have contributed to this phenomenon, a few appear particularly significant. Perhaps foremost is the realization that two of the most prevalent cancers which afflict women and men; that is, breast and prostate, have essential hormonal component(s) to their etiologies. This should not surprise us since the high frequency of these cancers in human populations has to date not been attributed to any exogenous physical, environmental, or dietary factor(s). A similar argument may be applied to other less prevalent but equally important cancers including ovarian, endometrial, testicular, cervico vaginal, pituitary, thyroid, and sex hormone-associated hepatic neoplasms. The Office of ResearcTable of ContentsIntroductions.- Introductory Remarks.- Opening Address Important Questions in Women’s Health Research: Determining the Influence of Hormones on Health.- Symposium Presentations Mammary Carcinogenesis: A Unifying Hypothesis.- Regulation of Cytochrome P-450 and Carcinogenesis: Peroxisome Proliferator-Activated Receptor and Dioxin Receptor.- State Of The Art Lectures.- 1 Cell Cycle and Cell Proliferation.- 2 Role of a Cell Cycle Regulator in Hereditary and Sporadic Cancers.- 3 Molecular Cytogenetics of Solid Tumor Progression.- 4 Nucleocytoplasmic Shuttling of Estrogen Receptors Is Blocked by “Pure Antiestrogens”.- I. Epidemiology: Hormonal Cancers.- Causality in Hormone Associated Human Cancers.- 5 Breast Cancer Incidence in Women Exposed to Estrogen and Estrogen-Progestin Replacement Therapy.- 6 Breast Cancer Trends in Women in Sweden, the UK, and the USA in Relation to Their Past Use of Oral Contraceptives.- 7 Gene Expression in Familial Breast Cancer: A Genetic-Epidemiology Study of Premenopausal, Bilateral Breast Cancer.- 2. Breast/Mammary Gland.- The Importance of Human Breast Development in Mammary Carcinogenesis.- 8 Breast Susceptibility to Carcinogenesis.- 9 Hormones, Growth Factors and Gene Expression in Preneoplasias of the Mouse Mammary Gland.- 10 Pathogenesis of Ductal and Lobular Progestin-Induced Mammary Carcinomas in BALB/c Mice.- 3. Endometrium/Uterus.- 11 Is the hsp90 Connection Between Steroid Receptors and Immunosuppressant Binding Immunophilins Involved in the Control of Gene Transcription and Cell Growth?.- 12 Expression and Regulation of 17?-Hydroxysteroid Dehydrogenase Type 1 in Steroidogenic Cells and Estrogen Target Tissues.- Growth Factors in Endometrial Cancer.- 4. Kidney.- 13 Introduction Estrogens and Genitourinary Cancers of Syrian Hamsters.- 14 Interstitial Cell Origin of Estrogen-Induced Kidney Tumors in the Syrian Golden Hamster.- 15 Effects of Estrogens on Microtubule Assembly: Significance for Aneuploidy.- 16 Estrogen Carcinogenesis: A Sequential, Epi-Genotoxic, Multi-Stage Process.- 5. Liver.- Role of Estrogens in Liver Carcinogenesis.- 17 Hormonal Regulation of Hepatic Cell Proliferation and Apoptosis: Implications for Carcinogenesis.- 18 Mechanisms of Tamoxifen-Induced Genotoxicity and Carcinogenicity.- 19 Regulation of Growth-Associated Nuclear Transcription Factors During Growth Hormone-Regulated, Sex Differentiated Rat Liver Carcinogenesis.- 6. Prostate.- 20 Isolation of Differentially Expressed cDNAs from Prostate Cancer Cell Lines Using Differential Display PCR: Identification of an Androgen-Regulated Gene.- 21 Progression of LNCaP Human Prostate Carcinoma Cells: Androgen Receptor Activity and c-myc Gene.- 22 Regulation of Prostatic Growth and Gene Expression: Role of Stroma.- Concluding Remarks.- 23 Sex Hormones and Neoplastic Transformation.- CLINICAL FORUM: Risk and Benefits of Hormone Replacement Therapy and Oral Contraceptive Use.- Therapeutic Implications of Hormone Replacement Therapy and Oral Contraceptives.- 24 Postmenopausal Estrogen-Progestin Therapy in Relation to Cancers of the Endometrium and Breast.- 25 The Use of Hormone Replacement Therapy in Women Previously Treated for Breast Cancer.- 26 Cardioprotection by Hormone Replacement Therapy.- 27 Risk and Benefits of Oral Contraceptives.- 28 Oral Contraceptives and the Risk of Breast and Cervical Cancer.- Communications Session I. Epidemiology, Human Studies.- Some Aspects of Breast Cancer Epidemiology.- Risk of Breast Cancer Associated with Induced Abortion.- Family History of Breast Cancer as a Modifier of Other Risk Factors.- Oral Contraceptive Use and Reproductive Risk Factors for Breast Cancer: A Comparison of Results among Black and White Women.- Patterns of Cancer Mortality in Women Who Had Used Sex Steroid Hormones under Age 60.- Progestogen Use and Risk of Breast Cancer.- Five-Year Survival of Women with Breast Cancer According to Prior Use of Oral Contraceptives.- Plasma Prolactin and IGF-1 Levels in Young, Healthy, Nulliparous Women in Relation to Low Dose Oral Contraceptive Use.- Effect of a Low-Fat Diet on Estrogen and Bile Acid Metabolism in Normal Human Subjects.- Expression of GST? in Breast Cancer and its Relationship with the Expression of Estrogen Receptor and Progesterone Receptor.- p53 and Neu (c-erbB-2) Overexpression in Relation to Risk Factors for Breast Cancer.- Cost Effectiveness of Hormone Replacement Therapy in French Postmenopausal Women.- Tamoxifen Treatment Does Not Induce Endometrial Hyperplasia in Postmenopausal Women.- Uterine Myomas: A Model to Study Hormonal Regulation of Growth Related Genes.- Transforming Growth Factor ?1 Facilitates Cell Proliferation and Invasion in MAT-LyLu Prostatic Cancer Cells.- Quantitative Effects of Antiandrogen Therapy on High-Grade Prostatic Intraepithelial Neoplasia in Radical Prostatectomy Specimens.- Alterations in Circulating Levels of Androgens and PSA During Treatment with Finasteride in Men at High Risk for Prostate Cancer.- Session II. Cell & Molecular Biology, Metabolism.- Effect of Estradiol on MCF-7 Human Breast Cancer Cells: Ultrastructural Studies.- Estradiol and Tamoxifen Induce TGF-?l Gene Expression in Cultured Normal Human Breast Stromal Cells.- Estrogen and Anti-Estrogen Regulation of Amplified erbB2 Gene Expression in Human Breast Cancer Cells.- Evaluation of Conformational Changes in hER-HBD by Pharmacological Dissection of Hormone Dissociation Rates in a Homogeneous Hormone-Binding Assay.- Estradiol Promotion of Size and Number of Hepatic Enzyme-Altered Foci in Rats in the Absence of Cell Proliferation.- Expression of Liver-Enriched Transcription Factors During Progression in the Resistant-Hepatocyte Model.- Nuclear Protein Binding to the AP-1 and CRE Sites During Sex-Differentiated Promotion of Rat Liver Carcinogenesis.- Induction of Endometrial Cancer by Tamoxifen in the Rat.- Mechanisms of Anti-Estrogen and Retinoid Inhibition of Breast Cancer Cell Proliferation.- Bisphenol-A Disturbs Microtubule Assembly and Induces Micronuclei In Vitro.- Natural Estrogens Induce Modulation of Microtubules in Chinese Hamster V79 Cells in Culture.- Induction of Micronucleation, Spindle Disturbances, and Mitotic Arrest in Human Chorionic Villi Cells by 17?-Estradiol, Diethylstilbestrol, and Coumestrol.- Increased Nuclear IGF-I Receptor Level, Coupled with Attenuation in DNA Repair, Plays an Important Role in Estrogen-Induced Carcinogenesis.- Pattern of Reproductive Aging in Female Rats Can Affect Mammary Tumor Incidence.- Antiproliferative Activity of Luteolin, a Naturally-Occurring Edible Plant Flavone, Against Estrone-Induced Cell Proliferation in the Mammary Gland of Noble Rats.- Sex Hormone-Induced Prostatic Carcinogenesis in Noble Rats Involves Genetic Damage and Cell Proliferation.- Catechol Estrogen Analogs as Probes of Estrogen Carcinogenesis.- In-Vitro Metabolites of Coumestrol.
£40.49
Springer-Verlag New York Inc. A Clinical Information System for Oncology
Book SynopsisA Clinical Information System for Oncology describes a medical information system designed and implemented in a cancer center but with broad applicability to medical practice beyond the cancer center environment in both inpatient and outpatient settings. Regarded as forward looking in 1978, the system has the distinction of still being in production. Indeed, its functionality has continued to grow and its technical implementation to evolve with the changing technology over the last decade. The authors detail the functions supported by this unique system, illustrate how it assists in the care process, review its development history, and evaluate its impact on the delivery of care in terms of cost, user satisfaction, and efficacy. Unlike much information technology, the system is an active participant in medical decision making: it includes comprehensive tools for managing aTable of ContentsI. Introduction and Overview.- 1. The Oncology Clinical Information System.- 2. Data Management in Clinical Decision Making.- 3. Development History.- II. Functional Description.- 4. Clinical Data Management.- 5. Protocol-Directed Care.- 6. Pharmacy System.- 7. Hemapheresis System.- 8. General Administrative Functions.- III. Evaluation and Future Directions.- 9. Evaluation and Future Directions.- 10. Implementing OCIS at the Ohio State University.
£999.99
Springer-Verlag New York Inc. Head and Neck Management of the Cancer Patient
Book SynopsisThis book presents in a comprehensive way cur the clinical care of the patient with head and neck rent advances in the management of neoplasia cancer involvement and/or its complications. and associated complications of the head and Today''s complex treatments in oncology re neck. A broad range of clinical considerations is quire a comprehensive approach to effect a posi discussed following overviews of relevant basic tive result for the cancer patient whose facial biologic issues and the roles of various disci appearance and function are compromised. We plines. Each chapter has been structured to trust that physicians, dentists, nurses, dental stand by itself; at the same time, obvious rela hygienists, and individuals in the supportive ser tionships with other chapters have been noted. vices involved in the management of the cancer We are pleased that this book represents, in ouTable of ContentsI. Introduction.- 1. Cancer, its complications, and the head and neck.- 2. Pathology of malignancy.- 3. Biology and biochemistry of metastatic cells.- II. Principles Of Management.- 4. Principles of surgical oncology.- 5. Principles of radiation therapy.- 6. Principles of chemotherapy.- 7. Principles of immunology.- 8. Principles of bone marrow transplantation.- 9. Principles of infection management.- III. Diagnosis And Management Of Head And Neck Neoplasia.- 10. Initial detection and evaluation: intraoral neoplasms.- 11. Initial detection and evaluation: extraoral neoplasms.- 12. Diagnostic radiology for head and neck neoplasms with emphasis on computerized tomography.- 13. Neoplasms of the salivary glands.- 14. Nonmucosal neoplasms of the maxillofacial region.- 15. Surgical management of head and neck neoplasia.- 16. Radiotherapeutic management of head and neck neoplasia.- 17. Chemotherapeutic management of head and neck neoplasia.- 18. Assessment of success of treatment of head and neck neoplasia.- IV. Head And Neck Complications Of Cancer Therapy.- 19. Oral complications associated with hematologic neoplasms and their treatment.- 20. Head and neck neurologic complications of malignancy.- 21. Head and neck complications of bone marrow transplantation.- 22. Oral complications of radiation therapy.- V. Supportive Care.- 23. Prosthetic management.- 24. Standards for nursing care of the oral cavity.- 25. Psychosocial effect of cancer on the patient and the family.- 26. Nutrition in the patient with compromised oral function.- Appendix: Staging of head and neck neoplasia.
£161.99
Springer-Verlag New York Inc. Screening for Biological Response Modifiers Methods and Rationale
Book SynopsisThe observation in the 1950s that nitrogen mustard and other toxic chemicals could induce antitumor responses in patients with refractory lymphoma initiated a massive search for active chemotherapeutic agents.Table of Contents1. Biologic and Technical Considerations for the Design of Screening Procedures for the Assessment of Biological Response Modifiers.- 2. Procedures for Preclinical Screening of Biological Response Modifying Agents.- 3. Preclinical Evaluation of Individual Biological Response Modifiers.- 4. Clinical Correlations.
£999.99
Springer-Verlag New York Inc. Prostaglandins and Immunity
Book SynopsisProstaglandins, Leukotrienes, and Cancer is a multi-volume series that will focus on an emerging area of cancer research. In 1968, R.H. Williams first reported that elevated prostaglandin levels are present in human medullary car cinoma. Since that time, the concept that arachidonic acid metabolites may be in volved in cancer has expanded to include every aspect of the disease from cell transformation through metastasis. Prostaglandins and leukotrienes are generic terms used to describe a family of bioactive lipids produced from unsaturated fatty acids (principally from arachidonic acid) via the cyclooxygenase and lipoxygenase pathways, respec tively. Cyclooxygenase products consist of diverse products such as prosta glandin E2 (PGE2), prostacyclin (PGI2) and thromboxane A2 (TXA2), whereas lipoxygenase products consist of hydroperoxy fatty acids and mono-, di-and tri-hydroxy acidTable of Contents1. Prostaglandins, cellular immunity and cancer.- 2. Prostaglandins and expression of lymphocyte cytotoxicity.- 3. The role of PGE2 in the induction of suppressor cells in humans.- 4. The role of arachidonic acid metabolites in the function of murine suppressor cells.- 5. Control of antibody and autoantibody production by prostaglandin E.- 6. Effects of prostaglandins on in vivo immune and inflammatory reactions.- 7. Regulation of the immune response by eicosanoid acids.- 8. Regulation of prostaglandin synthesis by biological response modifiers and effect on natural killer cells and bone marrow.- 9. The role of arachidonic acid metabolites in the regulation of neutrophil function.
£999.99
Springer-Verlag New York Inc. Diagnosis and Management of Malignant Solid Tumors in Infants and Children
Book SynopsisThe field of pediatric oncology encompasses four groups of malignancies - acute leukemias, brain tumors, lymphomas and solid tumors. 1''he history, diagnosis and management of children with acute leukemias and lymphomas has been thoroughly examined in several excellent textbooks of pediatric hematology and oncology. Blain tumors have historically been managed by neurosurgeons and radiation therapists. 1''he role of the pediatric oncologist in the management of these patients is evolving. This book was written to provide a thorough historical evaluation of the most frequent solid tumors of children. A detailed examination of the natural history of these tumors is essential to the design and evaluation of therapeutic trials. The highly lethal nature of many of these tumors, the occurrence of some of them at several different primary sites and the rarity of these tumors have made syTable of Contents1. Introduction.- 2. Rhabdomyosarcoma.- 3. Retinoblastoma.- 4. Wilms’ Tumor.- 5. Neuroblastoma.- 6. Ewing’s Sarcoma.- 7. Osteosarcoma.- 8. Yolk Sac Tumor.- 9. Hepatoblastoma and Hepatocellular Carcinoma.- 10. Long Term Complications of Therapy.
£999.99
Springer-Verlag New York Inc. Oral Oncology
Book SynopsisA multidisciplinary approach to the problems related to the diagnosis, treat ment, and rehabilitation of patients with oral cancer and precancer is reflected in the various specialties of the authors who contributed to this book. Today, patients with tumors of the oral cavity are dealt with preferably by a team of specialists who have been properly trained in the field of oncology, who have learned to appreciate each other''s knowledge and experience, and who are able to operate as an integrated team. This book is intended for use by every physician and dentist involved in the diagnosis and management of oral cancer. It is ''presented in such a way as to be useful for both the physician in training as well as the specialist in the field of head and neck oncology. The text concentrates on the common as well as the unusual aspects. For those who look for more detailed information, Table of ContentsI. Diagnosis.- 1. Clinical and histopathological aspects of premalignant lesions.- 2. Squamous cell carcinoma: Clinical and histopathological aspects.- 3. Tumors of the minor salivary glands: Clinical and histological aspects.- 4. Clinical and histological aspects of oral malignancies, excluding squamous cell carcinomas and salivary gland tumours.- II. Treatment.- 5. Surgical treatment of malignant tumors of the oral cavity.- 6. Radiotherapy aspects of malignant diseases of the oral cavity.- 7. Chemotherapy of squamous head and neck cancer.- 8. Reconstructive surgery of the oral cavity.- 9. Prosthetic rehabilitation and dental care.
£999.99
Springer-Verlag New York Inc. Hemostatic Mechanisms and Metastasis
Table of Contents1. Is there Clinical Relevance for Therapies which Disrupt the Metastatic Cascade?.- I. Introduction.- II. Primary Cancer and Vascular Invasion.- A. Tumor Stage.- B. Histology and Differentiation.- C. Tissue of Origin.- III. Circulating Cancer Cells.- IV. Metastatic Potential of Metastases.- V. Summary.- 2. Overview of the Metastatic Cascade.- I. Is Metastasis a Random or Non-Random Process?.- A. Heterogeneity.- B. Clones.- C. Randomness or Non-Randomness.- D. Conclusions.- II. Release 1.- A. Site.- B. Detachment Factors.- 1. Growth-rate and detachment.- 2. Necrosis and detachment.- 3. Enzymes and detachment.- III. Invasion.- IV. Arrest.- A. Biophysical Aspects of Arrest.- B. The Role of Platelets and Fibrin in Arrest.- C. General Host Effects.- D. Repetitive Events.- V. Release 2.- VI. The Formation of Metastases from Micrometastases.- VII. Conclusions.- 3. Overview on Blood Coagulation Proteins.- I. Introduction.- II. Structural Characteristics of Serine Proteinases.- III. The Role of Vitamin K.- IV. Fibrinogen.- V. Regulation of Blood Coagulation.- A. The Intrinsic Pathway.- B. The Extrinsic Pathway.- C. The Relationship between the Intrinsic and Extrinsic Pathways.- VI. Inhibitors of Blood Coagulation.- VII. Role of Platelets in Blood Coagulation.- VIII. Fibrinolysis.- 4. The Microinjury Hypothesis and Metastasis.- I. The Silent Sector of the Metastatic Cascade.- II. The Microinjury Hypothesis.- III. Conclusion.- 5. Hemostatic Abnormalities in Tumor-Bearing Animals.- I. Introduction.- II. Animal Models of Dissemination.- III. Lung Colony Models.- IV. Spontaneous Metastasis Models.- V. Pathophysiological Mechanisms.- VI. Conclusions.- 6. Evidence for a Tumor Proteinase in Blood Coagulation.- I. Introduction.- II. Purification of Cancer Procoagulant.- III. Characterization of Cancer Procoagulant.- IV. Distribution of Cancer Procoagulant.- V. Tissue Factor as the Tumor Procoagulant.- VI. Rationale For Cancer Procoagulant.- 7. Relationship between Procoagulant Activity and Metastatic Capacity of Tumor Cells.- I. Introduction.- II. Fibrin and Tumors.- III. Cancer Cell Procoagulants.- IV. Role of Procoagulants in Metastasis.- A. Hematologic Phase Model.- B. Spontaneous Models.- V. Clinical Relevance.- 8. Fibrin Formation: Implications for Tumor Growth and Metastasis.- I. Introduction and Historical Background.- II. The Nature of Fibrin Deposits in Tissues.- III. Fibrin is a Component of the Tumor Microenvironment.- A. Guinea Pig Hepato (bile duct) Carcinomas.- 1. Line 1 carcinomas.- 2. Line 10 carcinomas.- B. Mouse Breast Carcinomas.- C. Human Tumors.- 1. Infiltrating ductal breast carcinoma.- 2. Hodgkin’s disease and other malignant lymphomas.- D. Conclusions.- IV. Tumor Secreted Mediators can Generate Tumor Associated Fibrin Deposits.- A. Tumor Secreted Vascular Permeability Factor (PF).- B. Tumor Associated Procoagulants.- 1. Tissue factor-like activity.- 2. Factor X cleaving activities.- 3. Shed plasma membrane vesicles.- 4. Thrombin-like and factor XIII-like activities.- V. Summary and Conclusions.- 9. Perspectives on the Role of Platelets in Hemostasis and Thrombosis.- I. Introduction.- A. Platelet Adhesion.- B. Platelet Release Reaction.- C. Platelet Aggregation.- D. Coagulant Activities of Platelets.- E. Role of Platelets in Contact Activation.- II. Interaction of Platelets with Coagulation Factors.- A. Interactions of Platelets with Factor VIII.- B. The Interaction of Platelets with Factor V.- C. Interactions of Platelets with Vitamin K-Dependent Clotting Factors.- D. The Role of Platelets in the Intrinsic Activation of Factor X and Prothrombin.- E. Platelet Activation as It Relates to the Conversion of Prothrombin to Thrombin.- III. Other Potential Consequences Of Platelet Activation.- 10. Mechanisms of Platelet Aggregation by Murine Tumor Cell Spheroids.- I. Introduction.- II. Experimental Systems.- III. Platelet-Vesicle Interactions.- A. Platelet Aggregating Activity Shed Spontaneously by Cells.- 1. Spontaneous shedding of vesicles by 15091A.- 2. Activity of vesicles isolated by sucrose density gradient centrifugation.- B. Platelet Aggregating Activity Released by Augmented Shedding.- 1. Isotonic low ionic strength medium.- 2. Urea.- 3. Trypsin.- IV. Conclusions.- 11. Heterogenous Mechanisms of Tumor Cell-Induced Platelet Aggregation with Possible Pharmacological Strategy Toward Prevention of Metastases.- I. Introduction.- II. Materials and Methods.- III. Results.- A. Tumors which Require Complement, a Vesicular Cell Surface, Sialo-Lipoprotein Component, Divalent Cation and a Stable Plasma Factor for Platelet Aggregation Activity.- B. Tumors which Aggregate Platelets via the Generation of Thrombin.- C. Tumors which Require a Trypsin Sensitive Protein for Platelet Aggregating Activity.- D. Effect of Pharmacologic Agents on the Three Mechanisms of Tumor-Induced Platelet Aggregation.- IV. Discussion.- 12. Tumor Cysteine Proteinases, Platelet Aggregation and Metastasis.- I. Cysteine Proteinases.- II. Tumor Proteolytic Enzymes and Metastasis.- III. Tumor Cysteine Proteinases and Metastasis.- A. Cysteine Proteinase Activity in Tumors.- B. Cysteine Proteinase Activity Released from Tumors.- C. Tumor Cysteine Proteinases and Platelet Aggregation.- IV. Summary.- 13. Arachidonate Metabolism in Platelets and Blood Vessels.- I. Introduction.- II. Arachidonate Metabolism.- A. Phospholipase Activity.- B. Cyclooxygenase Activity.- C. PGI2 Synthase and Thromboxane A2 Synthase.- D. Arachidonate Lipoxygenation.- E. Metabolism of Prostaglandins and Thromboxanes.- III. Mechanism of Action of TXA2 and PGI2.- IV. Summary.- 14. Prostacyclin/Thromboxanes and Tumor Cell Metastasis.- I. Introduction.- II. Platelets, Coagulation and Metastasis.- III. Prostacyclin, Thromboxanes, Platelets And Metastasis.- A. Prostacyclin Effects In Vivo and In Vitro.- 1. Prostacyclin effects on TCIPA.- 2. Prostacyclin effects on platelet-induced tumor cell adhesion in vitro.- 3. Prostacyclin effects on metastasis in vivo.- 4. Role of endogenous PGI2 in tumor metastasis.- 5. Effect of agents that stimulate or synergize with endogenous PGI2 production.- a. Agents that alter PGI2 metabolism.- b. Thromboxane synthase inhibitors.- IV. Conclusions.- 15. Evidence for Altered Arachidonic Acid Metabolism in Tumor Metastasis.- I. Introduction.- II. Normal Platelet and Vessel Wall Activity.- III. Platelets and Tumor Growth.- IV. Production of Prostaglandins by Tumor Cells.- V. Role of Prostaglandins in Tumor Metastasis.- VI. Summary.- 16. Calcium Channel Blockers: Inhibitors of Tumor Cell-Platelet-Endothelial Cell Interactions.- I. Calcium Channel Blockers.- II. Role of Platelets in Tumor Metastasis.- III. Rationale for Use of Calcium Channel Blockers as Antimetastatic Agents.- IV. Antiplatelet Effects of Calcium Channel Blockers.- A. Platelet Aggregation Induced by Chemical Agonists.- B. Platelet Aggregation Induced by Tumor Cells.- C. Platelet-Enhanced Adhesion of Tumor Cells to Endothelium.- V. Antmetastatic Effects of Calcium Channel Blockers.- VI. Summary.- 17. Evidence for the Antimetastatic Effects of Coumarin Derivatives.- I. Background.- II. Experimental Models.- A. Lung Colonies.- B. Spontaneous Metastases.- III. Anticoagulants and Tumor Metastases.- IV. Coumarin Derivatives.- A. Pharmacology and Toxicology of Coumarins.- B. Antitumor Effects of Coumarins.- C. Antimetastatic Effects of Coumarin Derivatives.- D. Vitamin K Deficiency and Experimental Metastases.- V. The Vitamin K Dependent Cancer Procoagulant.- VI. Coumarin Derivatives and Macrophages.- VII. Conclusion.- 18. Mitogenic Stimulation of Tumor Cells by Platelet Derived Growth Factors.- I. Introduction.- II. Platelet-Derived Growth Factor for Mesenchymal Cells (PDGF1).- III. Platelet-Derived Growth Factor for Transformed Cells (PDGF 2).- IV. Transforming Growth Factors (TGF) From Tumor Cells.- V. Clinical Trial — Adjuvant Aspirin Therapy in Colo-Rectal Cancer.- A. Patient Selection and Treatment Protocol.- B. Results.- C. Future Directions.- 19. Role of the Vascular Endothelium in Hemostasis.- I. Structure of Endothelium.- II. Antithrombotic Functions of Endothelium.- A. Surface Charge.- B. Heparin-Like Substances.- C. Proteinase Inhibitors.- D. Thrombin and the Endothelium.- E. Endothelium and Fibrinolysis.- F. Other Surface Membrane Properties.- G. Prostacyclin and Endothelium.- III. Prothrombotic Functions of Endothelium.- A. Thrombogenic Glycoproteins.- B. Changes in Endothelial Surface.- IV. Interaction of Endothelium with Blood Cells.- V. Summary.- 20. The Cellular Interactions of Metastatic Tumor Cells with Special Reference to Endothelial Cells and their Basal Lamina-Like Matrix.- I. Introduction.- II. Cellular Interactions of Tumor Cells in Circulation.- III. Interactions of Tumor Cells with Vascular Endothelium.- IV. Degradation of Endothelial Basal Lamina by Tumor Cells.- V. Interactions of Tumor Cells with Intact Blood Vessels.- VI. Summary.- 21. Interaction of Tumor Cells with the Basement Membrane of Endothelium.- I. Introduction.- II. Structure and Function of Basement Membranes.- III. Attachment of Tumor Cells to Basement Membranes.- A. Selection for Metastatic Cells by Binding to Laminin or Fibronectin.- B. Tumor Cell Surface Receptors for Laminin.- C. Molecular Structure and Function of Laminin and Proteinase-Derived Fragments of Laminin.- D. Adhesive Behavior of Metastatic Cells.- IV. BM Degradation Mediated By Tumor-Cell Derived Proteolytic Enzymes.- A. Role of Type IV Collagenase and Type V Collagenase.- B. Role of Plasminogen Activator and Plasmin.- C. Enzymatic Cascade for BM Degradation.- V. Tumor Cell Locomotion into Vacancy Created By Proteolytic Degradation of the BM.- VI. Potential Significance of Metastatic Cell Degradation of the BM To Diagnosis and Therapy of Human Cancer.- 22. Hemostatic Alterations in Cancer Patients.- I. Thromboembolic Disorders.- II. Hemorrhagic Disorders.- III. Laboratory Abnormalities.- A. Routine Tests.- B. Fibrinopeptide A Measurements.- IV. Summary.- 23. Historical Overview of Clinical Experience with Anticoagulant Therapy.- I. Introduction.- II. Early Observations and Hypotheses.- III. The Coagulation Pathway and the Incidence of Cancer.- IV. Therapeutic Trials of Anticoagulation in Cancer Patients.- A. Uncontrolled or Historically Controlled Trials.- 1. Warfarin trials.- 2. Heparin trials.- 3. Miscellaneous anticoagulants.- B. Concurrently Controlled Trials of Anticoagulation.- C. Summary of Therapeutic Trials.- 1. Reported toxicities in therapeutic trials of anticoagulation for cancer.- 2. Comments on human trials to date.- V. Summary.- 24. Rationale for Anticoagulant Treatment of Cancer.- I. Introduction.- II. Possible Tumor Cell Interaction with Hemostatic Mechanisms.- A. Platelets.- B. Fibrin.- III. Discussion.- 25. The Design and Execution of Anticoagulant Therapy Trials in Cancer.- I. Introduction.- II. Effects of Reduced Blood Coagulability on Cancer.- III. Clinical Trials of Anticoagulants in Cancer.- A. The Case for Prospective, Randomized Anticoagulant Studies.- B. Blinding of Anticoagulant Trials.- IV. Discussion.- Appendix I.- Appendix II.- 26. Experimental and Clinical Experience with Pyrimido — Pyrimidine Derivatives in the Inhibition of Malignant Metastasis Formation.- I. Introduction.- II. The Effect of Pyrimido — Pyrimidine Derivatives on Cell Growth and Metastasis Formation in Animals.- III. Clinical Results of Metastasis Prophylaxis in Malignant Human Tumors Using the Pyrimido — Pyrimidine Derivative Mopidamole (Ra 233).- IV. Conclusions.- 27. Current Clinical Trials with Anticoagulant Therapy in the Management of Cancer Patients.- I. Introduction.- II. Historical Overview.- A. Clinical Background.- B. Research Background.- III. Completed Clinical Trials.- IV. Summary of Current Concepts for Clinical Trials.- A. Current Clinical Trials.- V. Summary.
£999.99
Springer-Verlag New York Inc. Oral Complications of Cancer Chemotherapy
Book SynopsisThis new work on oral complications of cancer chemotherapy is edited by two dentists who have made pioneering contributions in this previously neglected area. Their efforts have established the invaluable role of the dentist in oncologic research and cancer patient management. The editors have collected nine chapters that will be of interest to dentists and dental hygienists, oncology nurses, and all physicians treating cancer patients with chemo therapeutic agents. Background chapters on oral complications of cancer chemotherapy, the pharmacology of chemotherapeutic agents, and principles of infection management and prevention set the stage for more specific chapters focusing on prevention and treatment of chemotherapy induced oral and dental disorders. Valuable contributions to the supportive care of the cancer patient are contained in this book. A full comprehension of this boTable of Contents1. Epidemiology, Frequency, Distribution, Mechanisms, and Histopathology.- 2. Pharmacology of Chemotherapeutic Agents.- 3. Principles of Infection Management and Prevention.- 4. Oral Microbial Changes and Infections during Cancer Chemotherapy.- 5. Bacterial Infections: Periodontal and Dental Disease.- 6. Oral Complications of Bone-Marrow Transplantation.- 7. Dental Management of Patients Receiving Chemotherapy.- 8. Guidelines for Oral Hygiene, Denture Care, and Nutrition in Patients with Oral Complications.- 9. Establishment of a Comprehensive Oral Oncology Program: Services, Facilities, and Management.
£116.99
Springer-Verlag New York Inc. Bladder Disease
Book SynopsisIn 1996, the National Bladder Foundation (NBF) was founded by a dedicated group of physicians and researchers propeIled by the urgent need to find better treatments for bladder disease. Committed to increasing bladder disease research and to supporting its research community, the NBF coordinates and sponsors the International Bladder Symposium (IBS) in Washington, DC. Now considered to be a premier scientific assembly, the IBS brings together international leaders in bladder disease research to present and discuss their findings. It is the only international conference where all areas of bladder disease research are exclusively covered and where bladder disease researchers are provided with a unique opportunity to share their results and theories. IBS participants contributed the research papers included in this publication in 2000 and 2001. AIl substantial areas of bladder disease research are addressed, including oncology and ceIlular biology, neurophysiology, neurogenic bladder and Table of ContentsOncology and Cellular Biology.- 1. Recent Developments in the Treatment of Bladder Cancer.- 2. Interferon-? Response and Signal Transduction Pathway in Transitional Carcinoma Cell Lines.- 3. Molecular Cloning and Expression of Uroplakins in Transitional Cell Carcinoma.- 4. Application of a Novel Protein Chip Mass Spectrometry Technology for the Identification of Bladder Cancer-Associated Biomarkers.- 5. The Photodynamic Diagnosis (PDD) for Early Detection of Carcinoma and Dysplasia of the Bladder.- 6. Prediction of Lymph Node Metastasis Based on P53 and nm23-Hl Expression in Muscle Invasive Grade III Transitional Cell Carcinoma of Bladder.- 7. Detection of HER-2/neuCEP 17 Mutations at Invasive Bladder Cancer.- 8. Ki67, P53, nm23, and DNA Cytometry in Bladder Cancer: Potential Markers for Detection of Recurrence.- 9. Comparison of Cytology and Nuclear Matrix Protein 22 (NMP 22) for the Detection and Follow-Up of Bladder Cancer.- 10. The Effect of Contrast Material on Transitional Cell Carcinoma Viability.- 11. Fluorodeoxyglucose Positron Emission Tomography Studies in the Diagnosis and Staging of Transitional Cell Carcinoma.- 12. Radiochemotherapy in Locally Invasive Non-Metastatic Carcinoma of the Bladder.- 13. Gene and Antisense Therapy of Bladder Cancer.- 14. Tumor Suppressor Genes of Bladder Cancer and Potential for Gene Therapy.- Muscle, Matrix, and Obstruction.- 15. Molecular Response of the Bladder to Obstruction.- 16. The Role of Lipids and Lipid Metabolites in Urinary Bladder Dysfunction Induced by Partial Outlet Obstruction.- 17. Intercellular Communication and Bladder Function.- 18. Ischemia as an Etiological Factor in Bladder Instability: Implications for Therapy.- 19. Effect of Chronic Ischemia on Bladder Structure and Function.- 20. Ultrastructural Diagnosis of Neuropathic Detrusor Overactivity: Validation of a Common Myogenic Mechanism.- 21. Serial Changes of Smooth Muscle Cell Phenotypes in Rat Urinary Bladder Following Partial Outflow Obstruction.- 22. Study of Detrusor Dysfunction Due to Outlet Obstruction: Link Between Analysis of Uroflows of Men with Benign Prostatic Hyperplasia and Animal Studies.- 23. Ultrasonic Measurement of Bladder Weight as a Novel Urodynamic Modality.- Neurophysiology, Neurogenic Bladder, and Incontinence.- 24. Experimental Neurogenic Cystitis.- 25. Murine In Vitro Whole Bladder Physiology.- 26. Ca2+ Sparks and KCa Channels: Novel Mechanisms to Relax Urinary Bladder Smooth Muscle.- 27. The Effect of Intravesical Capsaicin and Resiniferatoxin in Neurogenic Bladder Dysfunction.- 28. On the Physioanatomy of Micturition and Urinary Continence-New Concepts.- 29. Stress Urinary Incontinence: New Concept of Pathogenesis and Treatment by Pudendal Canal Decompression.- 30. Transcutaneous Electrovesicogram in Normal Volunteers and Patients with Interstitial Cystitis, Neurogenic Bladder, Benign Prostatic Hyperplasia, and after Cystectomy.- 31. Extracorporeal Electromagnetic Stimulation for Urinary Incontinence and Bladder Disease.- 32. Pubovaginal Sling Surgery without Using Abdominal Leak Point Pressure: An Outcomes Analysis.- 33. The Use of Synthetic Materials in Pubovaginal Sling.- 34. Surgical Implantation of the Synthetic Sling (The 6-Point Fixation Technique and Weight-Adjusted Spacing Nomogram): Technique and Results.- 35. Reconstructive Surgery in Neuropathic Bladder.- 36. The Role of the Simple Cystectomy in Urologic Surgery.- Immunology, Inflammation, and Infection.- 37. Neurogenic Inflammation of the Bladder.- 38. Urine-Induced Apoptosis in Cultured Bladder Urothelial Cells.- 39. Bacillus of Calmette and Guerin Modulates Nuclear Factor Kappa ? in Two Urothelial Carcinoma Cell Lines.- 40. Induction of Urothelial Cell Proliferation by Fibroblast Growth Factor-7 in RAG 1-Deficient Mice.- 41. Development of a Recombinant FimCH Vaccine for Urinary Tract Infections.- 42. Intravesicular Pain Mapping.- 43. A Hypothesis for the Etiology of Interstitial Cystitis.- 44. Pentosanpolysulfate (Elmiron) is a Potent Inhibitor of Mast Cell Histamine Secretion.- 45. The Efficacy of Intravesicular Sterile Sodium Chondroitin Sulfate 0.2% in Potassium Tested Positive Patients with Interstitial Cystitis.- 46. Cystectomy Causes Immunosuppression in Bladder Cancer.- New Frontiers and Therapies.- 47. Nocturia.- 48. The Fate of Urinary Bladder Smooth Muscle after Outlet Obstruction—A Role for the Sarcoplasmic Reticulum.- 49. Alteration of Collagen Three-Dimensional Architecture in Noncompliant Human Urinary Bladder.- 50. Modulation of Angiogenesis: Experimental Strategies and Potential Therapeutic Applications.- 51. Methods of Testing Urethral Resistance in the Female Rat.- 52. Virtual Reality Surgical Simulation for Lower Urinary Tract Endourologic Surgery.- 53. Autologous Muscle Transfer for Reconstruction of the Lower Urinary Tract.- 54. Effectiveness of Denuding the Intestinal Mucosa by Submucosal Injection in the Porcine Model.- 55. Urinary Diversion in the Management of Chronic Perineal Skin Ulceration in Spinal Cord Injured Patients Following Sphincterotomy.- 56. The Artificial Urinary Bladder.- 57. Comparison of the Breaking Strength of Polyglactin Mesh in Urine, Serum, and Cell Culture Media.- 58. Growth of Cultured Human Urothelial Cells Into Stratified Urothelial Sheet Suitable for Autografts.- 59. Future Perspectives in Bladder Reconstruction.
£999.99
Springer-Verlag New York Inc. Management of Soft Tissue Sarcoma
Book SynopsisManagement of Soft Tissue Sarcoma addresses the diagnosis and best current management of adult soft tissue sarcomas. Both clinical and molecular diagnoses are addressed, and tumor histopathology is employed as the basis of treatment recommendations including surgery, radiation therapy, systemic therapy and novel therapeutics.Trade Review“This is an excellent monograph of the Diagnosis, Pathology, Imaging, Treatment, and Surgical outcomes of sarcomas and related tumors of the soft tissue variety. … This is a very good book for oropedic surgeons, patologists, students, and clinicians with an interest in the diagnosis and treatment of high and low grade liposarcomas, leomyosarcomas, benign type lesions, and other kind of subcutaneous tumors with distant lung, brain, and liver metastases.” (Joseph J. Grenier, Amazon.com, October, 2015)“This is an impressive book. Written by a surgeon, a pathologist and an oncologist, the book draws heavily on the Memorial Sloan-Kettering Cancer Center soft tissue sarcoma (STS) database. … it is a book that should be in the library of any sarcoma unit and will appeal to the sub-specialist in Orthopaedic Oncology.” (Robert U. Ashford, European Journal of Orthopaedic Surgery & Traumatology, Vol. 24, 2014)“The book is laid out in 27 chapters, with an impressive inclusion of a wide array of sarcoma histology. One of the real strengths of the book is the quality and number of images, figures, tables, and graphs. … The overall outline of the text is well done. … This book is a unique and important addition to the sarcoma literature. … this edtion should find itself on every medical oncologist’s bookshelf … .” (Larry C. Daugherty and Sanjay P. Bagaria, Journal of Radiation Oncology, Vol. 3, 2014)Table of ContentsPrefaceIntroduction 1. General Description2. Natural History – Importance of Size, Site, Histopathology3. General Statement as to Efficacy of Surgery / Chemotherapy / Radiation Therapy Part I. Management by Histopathology - Introduction4. Gastrointestinal Stromal Tumor (GIST)5. Liposarcoma 6. Leiomyosarcoma 7. Undifferentiated Pleomorphic Sarcoma (UPS) (Malignant Fibrous Histiocytoma - MFH) / Myxofibrosarcoma 8. Synovial Sarcoma 9. Malignant Peripheral Nerve Sheath Tumor (MPNST) / Triton Tumor10. Desmoid Tumor / Deep-Seated Fibromatosis (Desmoid-type Fibromatosis)11. Solitary Fibrous Tumor / Hemangiopericytoma12. Fibrosarcoma and its Variants13. Vascular Sarcomas14. Epithelioid Sarcoma15. Sarcomas more Common in Children 16. Radiation Induced Sarcoma17. Alveolar Soft Part Sarcoma 18. Clear Cell Sarcoma / Melanoma of Soft Parts 19. Desmoplastic Small Round Cell Tumor 20. Extraskeletal Myxoid Chondrosarcoma 21. Other Uterine Sarcomas22. Extraskeletal Osteogenic Sarcoma23. Sustentacular Tumors of Lymph Tissue24. Uncommon / Unique Sites Part II. Benign and Less Aggressive Lesions - Introduction25. Mostly Benign / Rarely Metastasizing26. Benign Tumors27. Reactive Lesions10. Desmoid Tumor / Deep-Seated Fibromatosis (Desmoid-type Fibromatosis)11. Solitary Fibrous Tumor / Hemangiopericytoma12. Fibrosarcoma and its Variants13. Vascular Sarcomas14. Epithelioid Sarcoma15. Sarcomas more Common in Children 16. Radiation Induced Sarcoma17. Alveolar Soft Part Sarcoma 18. Clear Cell Sarcoma / Melanoma of Soft Parts 19. Desmoplastic Small Round Cell Tumor 20. Extraskeletal Myxoid Chondrosarcoma 21. Other Uterine Sarcomas22. Extraskeletal Osteogenic Sarcoma23. Sustentacular Tumors of Lymph Tissue24. Uncommon / Unique Sites Part II. Benign and Less Aggressive Lesions - Introduction25. Mostly Benign / Rarely Metastasizing26. Benign Tumors27. Reactive Lesions2. Natural History – Importance of Size, Site, Histopathology3. General Statement as to Efficacy of Surgery / Chemotherapy / Radiation Therapy Part I. Management by Histopathology - Introduction4. Gastrointestinal Stromal Tumor (GIST)5. Liposarcoma 6. Leiomyosarcoma 7. Undifferentiated Pleomorphic Sarcoma (UPS) (Malignant Fibrous Histiocytoma - MFH) / Myxofibrosarcoma 8. Synovial Sarcoma 9. Malignant Peripheral Nerve Sheath Tumor (MPNST) / Triton Tumor10. Desmoid Tumor / Deep-Seated Fibromatosis (Desmoid-type Fibromatosis)11. Solitary Fibrous Tumor / Hemangiopericytoma12. Fibrosarcoma and its Variants13. Vascular Sarcomas14. Epithelioid Sarcoma15. Sarcomas more Common in Children 16. Radiation Induced Sarcoma17. Alveolar Soft Part Sarcoma 18. Clear Cell Sarcoma / Melanoma of Soft Parts 19. Desmoplastic Small Round Cell Tumor 20. Extraskeletal Myxoid Chondrosarcoma 21. Other Uterine Sarcomas22. Extraskeletal Osteogenic Sarcoma23. Sustentacular Tumors of Lymph Tissue24. Uncommon / Unique Sites Part II. Benign and Less Aggressive Lesions - Introduction25. Mostly Benign / Rarely Metastasizing26. Benign Tumors27. Reactive Lesions10. Desmoid Tumor / Deep-Seated Fibromatosis (Desmoid-type Fibromatosis)11. Solitary Fibrous Tumor / Hemangiopericytoma12. Fibrosarcoma and its Variants13. Vascular Sarcomas14. Epithelioid Sarcoma15. Sarcomas more Common in Children 16. Radiation Induced Sarcoma17. Alveolar Soft Part Sarcoma 18. Clear Cell Sarcoma / Melanoma of Soft Parts 19. Desmoplastic Small Round Cell Tumor 20. Extraskeletal Myxoid Chondrosarcoma 21. Other Uterine Sarcomas22. Extraskeletal Osteogenic Sarcoma23. Sustentacular Tumors of Lymph Tissue24. Uncommon / Unique Sites Part II. Benign and Less Aggressive Lesions - Introduction25. Mostly Benign / Rarely Metastasizing26. Benign Tumors27. Reactive Lesions
£134.99
Springer-Verlag New York Inc. Papillomaviruses in Human Cancer
Book Synopsis1. Human Papillomaviruses and Cancer: A Retrospective.- 2. Regulation of E6 and E7 Oncogene Transcription.- 3. E6 Protein.- 4. E7 Protein.- 5. Immunological Aspects of the E6 and E7 Oncogenes: Tools for Diagnosis and Therapeutic Intervention.Table of Contents1. Human Papillomaviruses and Cancer: A Retrospective.- 2. Regulation of E6 and E7 Oncogene Transcription.- 3. E6 Protein.- 4. E7 Protein.- 5. Immunological Aspects of the E6 and E7 Oncogenes: Tools for Diagnosis and Therapeutic Intervention.
£40.49
Lippincott Williams and Wilkins Biopsy Interpretation of the Skin
Book SynopsisPart of the popular Biopsy Interpretation Series, Biopsy Interpretation of the Skin: Primary Non-Lymphoid Cutaneous Neoplasia, Second Edition , is a concise, practical resource with a strong focus on diagnosis. It offers guidelines on how and when to biopsy the skin and provides superb coverage of common and uncommon non-lymphoid neoplasms of the skin. Focusing on the daily tasks and needs of the general pathologist, this updated Second Edition is an excellent bench reference and education resource for the interpretation of the most common skin biopsies. Incorporates recent advances in the biology of skin cancer which have led to important biologic therapies for melanoma, basal cell carcinoma, and squamous cell carcinoma. Includes new chapters on the clinical approach to surgical conditions of the skin and soft tissue tumors. Offers online access to 375 additional figures, plus an online multiple-choice test bank that is ideal for board exam preparat
£144.00
Taylor & Francis Inc Cancer Biomarkers
Book SynopsisThis unique synthesis of chapters from top experts in their fields, targets the very important and upcoming area of cancer biomarkers and the need for better and more rigorous design and clinical trial. The book covers several aspects of cancer molecular markers from innovation, screening, controversies and future directions. The primary target audience for the book includes PhD and MD students, researchers, biologists, medical doctors and professionals who are interested in mechanistic studies on cancer diagnosis and translational benefits from personalized cancer treatment using the new era of biomarkers.Table of ContentsImproving Research on Biomarkers for Early Detection and Screening of Cancers. Biomarkers of Oxidative Stress in Carcinogenesis. ß-Catenin: a Novel Biomarker and Therapeutic Target in Liver Cancer. Urine Biomarkers for Prostate Cancer Detection. Ectodomain Shedding as a Mechanism to Generate Cancer Biomarkers (Ectomarkers). The BRCT Signaling ‘landscape’: Emerging Concepts and Implications in Tumorigenesis and Cancer Diagnostics. Cellular Senescence and Cancer Development: Antagonistic and Synergistic Relations. Micro-RNAs: From Regulators of Gene Expression to Cancer Biomarkers. Targeting PARP-1 in Breast Cancer: The Paradigm of a DNA Repair-based Therapeutic Strategy. Statins in Prostate Cancer: Prevention and Treatment. Mechanistic Aspects of Oxidative Stress Involvement in Human Environmental and Occupational Carcinogenesis.
£133.00
Demos Medical Publishing Principles of Clinical Cancer Research
Book SynopsisPrinciples of Clinical Cancer Research provides comprehensive coverage of the fundamentals of clinical cancer research, including the full spectrum of methodologies used in the field. For those involved in research or considering research careers, this book offers a mix of practical advice and analytical tools for effective training in theoretical principles as well as specific, usable teaching examples. The clinical oncologist or trainee will find a high-yield, practical guide to the interpretation of the oncology literature and the application of data to real-world settings. Valuable for both researchers and clinicians who wish to sharpen their skills, this book contains all of the cornerstones and explanations needed to produce and recognize quality clinical science in oncology.Written from the physician-scientist's perspective, the book lays a strong foundation in preclinical sciences that is highly relevant to careers in translational oncology research along with coverage of population and outcomes research and clinical trials. It brings together fundamental principles in oncology with the statistical concepts one needs to know to design and interpret studies successfully. With each chapter including perspectives of both clinicians and scientists or biostatisticians, Principles of Clinical Cancer Research provides balanced, instructive, and high-quality topic overviews and applications that are accessible and thorough for anyone in the field.KEY FEATURES: Gives real-world examples and rationales behind which research methods to use when and why Includes numerous tables featuring key statistical methods and programming commands used in everyday clinical research Contains illustrative practical examples and figures in each chapter to help the reader master concepts Provides tips and pointers for structuring a career, avoiding pitfalls, and achieving success in the field of clinical cancer research Access to fully downloadable eBook
£110.29
Live Stronger Faster 90 All Natural Lung Cancer Meal and Juice
Book Synopsis
£18.99
Live Stronger Faster 142 Lung Cancer Juice, Salad, and Meal Recipes:
Book Synopsis
£17.99
Oncology Nursing Society Manual for Radiation Oncology Nursing Practice
Book SynopsisCaring for an individual receiving radiation therapy as part of overall cancer care requires a patient-focused approach. To support this patient population, nurses across treatment settings must constantly expand and refine their knowledge of advancements in radiation therapy technology, research, and evidence-based practice.In this fifth edition of the Oncology Nursing Society Manual for Radiation Oncology Nursing Practice and Education, nurses of all experience levels will advance their knowledge of radiation biology and protection, diverse radiation therapy modalities, combination treatments, site- and disease-specific issues, symptom management, special populations, and much more.This expanded and revised resource includes significant updates and additions to best reflect advancements in radiation oncology. New topics address patients with cognitive changes and dementia, general distress and coping, special populations including individuals with mental illness, special needs related to late effects of treatment and cardiac toxicities, and the latest treatment modalities. This manual will serve oncology nurses, advanced practice clinicians, educators, and administrators seeking the education and skills required to care for patients receiving radiation therapy and their families.
£198.55
Collective Ink You Can Beat Lung Cancer – Using
Book SynopsisCan you overcome lung cancer without harsh chemicals, surgery and debilitation? Are alternative interventions effective? Why do conventional physicians not use them? Can you prevent cancer recurrences and live into old age without chronic diseases and prescribed medications? This book answers these and other questions. This is one of the most comprehensive books available on alternative treatments for lung cancer. It explains the treatments used successfully by a health professional/cancer survivor of 36 years and by some of the leading medical and health practitioners currently in the field. G. Edward Griffin, Author of World Without Cancer, The Politics of Cancer Therapy, and other books and films. Recipient of the Telly Award for Excellence in Television Production. President of American Media.Trade ReviewThis is one of the most comprehensive books available on alternative treatments for lung cancer. It explains the treatments used successfully by a health professional/cancer survivor of 36 years and by some of the leading medical and health practitioners currently in the field. It will be useful, not just for the lay reader, but also for therapists and others with a scientific background. --G. Edward Griffin, Author of World Without Cancer, The Politics of Cancer Therapy, and other books and films. Recipient of the Telly Award for Excellence in Television Production. President of American Media. If you are ever diagnosed with advanced cancer, the odds are very good that your oncologist will tell you that unless you immediately consent to chemotherapy you are going to die. This is a lie! I know, I have been treating conventional chemotherapy failures for years. Other than for leukemia or lymphoma, conventional chemotherapy is almost always a death sentence. There are so many more effective ways to treat advanced cancer, and Dr. Carl Helvie's book, You Can Beat Lung Cancer: Using Alternative/Integrative Interventions, describes some of the most effective. In addition, his book is packed with references and information sources that will help anyone fighting cancer learn more about how to go about it successfully. --Frank Shallenberger, MD, HMD, ABAAM, Medical Director, The Nevada Center of Alternative Medicine, Editor: Real Cures Newsletter and Author This is a valuable piece of writing, to give people hope that there are other ways back to health from cancer, than the 'slash, burn and poison' offered by conventional oncology. --Robert A. Eslinger, D.O., H.M.D. | Medical Director, Reno Integrative Medical Center
£15.19
Healthy Vegan Recipes Vegan Protein Smoothies: Superfood Vegan Smoothie
Book Synopsis
£999.99
Bedford Square Publishers The Cancer Guide
Book Synopsis
£999.99
S.H.E. Publishing, LLC I Had Cancer, Cancer Never Had Me
£20.89
Wolters Kluwer Health Handbook of Targeted Cancer Therapy and Immunotherapy: Gastrointestinal Cancer
Designed for quick, everyday reference, Handbook of Targeted Cancer Therapy and Immunotherapy: Gastrointestinal Cancer provides a practical overview of this rapidly advancing field. Comprehensive yet concise, this easy-access resource by Dr. Milind Javle of MD Anderson Cancer Center and Dr. Mitesh J. Board of Mayo Clinic helps you filter and apply the most recent discoveries as they pertain to specific tumor types, actionable molecular targets, and clinical performance of investigational targeted agents and combinations of agents. Covers gastrointestinal cancer targets—stage 1, 2, and 3 trials and preliminary results, as well as approved therapies. Includes sections on Sequencing Technologies, and Targeted and Immunotherapy Agents. Organizes information by tumor type, pathway, and drug name, so you can approach clinical challenges from any direction. Highlights FDA approvals throughout. Pocket-sized and color coded to help you find information quickly and easily. , Enrich Your eBook Reading Experience Read directly on your preferred device(s), such as computer, tablet, or smartphone. Easily convert to audiobook, powering your content with natural language text-to-speech. ,
£46.08
Wolters Kluwer Health The Washington Manual of Cardio-Oncology: A
Book SynopsisWritten by experts in cardiovascular disease, hematology, and oncology, The Washington Manual® of Cardio-Oncology: A Practical Guide for Improved Cancer Survivorship is a clinically relevant, easy-to-use primer on the detection, management, and improved cardiovascular-based patient outcomes in adults undergoing treatment for cancer or who have previously survived cancer therapy. Edited by Drs. Daniel J. Lenihan, Joshua D. Mitchell, and Kathleen W. Zhang, this concise yet comprehensive manual provides high-yield information that reflects today’s advances in risk stratification, early diagnosis, and treatment of cardiovascular disease—all in an easy-access, concisely bulleted format for on-the-go reference. Discusses the multitude of complex adverse effects of chemotherapy, targeted therapy, immunotherapy, and radiation therapy to help optimize quality of life and prolong survival in this vulnerable patient population. Includes chapters on how cancer therapy affects the myocardium, valves, pericardium and cardiac electrical system including handy reference tables on typical side effects of commonly used cancer therapies. Provides practical guidance in an easy-to-follow format that covers definition, associated drugs/therapies, epidemiology, diagnosis (history, physical exam, and diagnostic testing), treatment, and outcome/prognosis. Covers the role of non-invasive imaging modalities in the diagnosis and screening for cardiovascular disease including echocardiography, MRI, and nuclear imaging. Addresses frequently encountered clinical scenarios such as preoperative or pre-high-risk treatment evaluation with up-to-date expert consensus recommendations. Details emerging treatments and optimal use of non-invasive imaging in cardiac amyloidosis. Features easy-to-use flow-charts and tables that aid in the differentiation of cardiac masses. The Washington Manual® is a registered mark belonging to Washington University in St. Louis to which international legal protection applies. The mark is used in this publication by Wolters Kluwer Health under license from Washington University. Enrich Your eBook Reading Experience Read directly on your preferred device(s),such as computer, tablet, or smartphone. Easily convert to audiobook,powering your content with natural language text-to-speech.
£999.99
Createspace Independent Publishing Platform 107 Powerful Breast Cancer Meal and Juice
Book Synopsis
£16.12
Springer Nature Switzerland AG Pigmented Ethnic Skin and Imported Dermatoses: A Text-Atlas
a huge range and FREE tracked UK delivery on ALL orders.
£999.99
Springer Nature Switzerland AG Chronic Lymphocytic Leukemia
Book SynopsisThis book summarizes current knowledge on chronic lymphocytic leukemia (CLL), taking into account the most recent research. All aspects are considered, including pathophysiology, clinical presentation, diagnosis, prognosis, treatment, follow-up, and complications and their management. Readers will find important information on the various prognostic markers as well as practical guidance on the use of different diagnostic procedures. A key focus of the book is the changing treatment paradigm in CLL as progress in understanding of pathogenesis and pathophysiology leads to the identification of new potential therapeutic targets. General treatment concepts are clearly described, and it is explained how choice of treatment for CLL depends on stage, age, and performance status as well as specific genetic aberrations. In addition, frontline therapeutic strategies for disease relapse, including allogeneic stem cell transplantation, are reported. Looking beyond CLL, the diagnosis and therapy of T-cell prolymphocytic leukemia and T-cell large granular lymphocyte leukemia, two rare CLL-related entities, are addressed. Table of ContentsPathophysiolgoy.- Diagnostics.- Clinical Presentation.- Prognostic Markers.- Treatment.- Follow-up and Complications.- Related Entities.
£999.99
Springer Nature Switzerland AG International Manual of Oncology Practice: iMOP - Principles of Oncology
a huge range and FREE tracked UK delivery on ALL orders.
£999.99